Arcellx (ACLX) Amortization of Deferred Charges (2022 - 2025)
Arcellx's (ACLX) quarterly Amortization of Deferred Charges came in at $190000.0 in Q3 2025, up 45.04% year-on-year from $131000.0 in Q3 2024, and up 1.06% quarter-over-quarter from $188000.0 in Q2 2025.
Arcellx (ACLX) Amortization of Deferred Charges (2022 - 2025) Analysis & Trends
Arcellx's Amortization of Deferred Charges history runs 4 years deep, the most recent figure standing at $190000.0 for Q3 2025.
- On a quarterly basis, Amortization of Deferred Charges rose 45.04% year-over-year to $190000.0 in Q3 2025; TTM through Sep 2025 was $709000.0, a 78.91% decrease from a year earlier, with the FY2024 full-year figure at $3.3 million, up 227.72% from the prior year.
- Amortization of Deferred Charges climbed to $190000.0 in Q3 2025 per ACLX's latest filing, from $188000.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $2.9 million in Q1 2024 and bottomed at -$285000.0 in Q4 2022.
- The 4-year median for Amortization of Deferred Charges is $190000.0 (2025), against an average of $385800.0.
- Across the five-year window, Amortization of Deferred Charges jumped 836.45% in 2024 and plunged 93.59% in 2025, its largest moves.
- Year by year, Amortization of Deferred Charges stood at -$285000.0 in 2022, then soared by 169.12% to $197000.0 in 2023, then decreased by 26.4% to $145000.0 in 2024, then surged by 31.03% to $190000.0 in 2025.
- Per Business Quant, the three latest ACLX Amortization of Deferred Charges figures stand at $190000.0 (Q3 2025), $188000.0 (Q2 2025), and $186000.0 (Q1 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,801.52 Bn | 66,801.23 Bn | - |
| 2 | Nanobiotix | 1,916.61 Bn | 1,916.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.65 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.94 Bn | 114.69 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.85 Bn | 61.09 Bn | 3.31 Bn |
| 7 | Belite Bio | 63.06 Bn | 63.06 Bn | - |
| 8 | Argenx Se | 55.74 Bn | 50.56 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.48 Bn | 37.48 Bn | - |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 190,000.00 |
| Sep 30, 2025 | 190,000.00 |
| Jun 30, 2025 | 188,000.00 |
| Jun 30, 2025 | 188,000.00 |
| Mar 31, 2025 | 186,000.00 |
| Mar 31, 2025 | 186,000.00 |
| Dec 31, 2024 | 145,000.00 |
| Dec 31, 2024 | 145,000.00 |
| Sep 30, 2024 | 131,000.00 |
| Sep 30, 2024 | 131,000.00 |
| Jun 30, 2024 | 131,000.00 |
| Jun 30, 2024 | 131,000.00 |
| Mar 31, 2024 | 2.90 Mn |
| Mar 31, 2024 | 2.90 Mn |
| Dec 31, 2023 | 197,000.00 |
| Dec 31, 2023 | 197,000.00 |
| Sep 30, 2023 | 244,000.00 |
| Sep 30, 2023 | 244,000.00 |
| Jun 30, 2023 | 259,000.00 |
| Jun 30, 2023 | 259,000.00 |